Cargando…

ARB might be superior to ACEI for treatment of hypertensive COVID‐19 patients

The administration of ACEI/ARB (angiotensin‐converting enzyme inhibitors/Angiotension II receptor blockers) in COVID‐19 (coronavirus disease 2019) patients with hypertension exhibits a lower risk of mortality compared with ACEI/ARB non‐users. In this context, an important question arises: is ACEI or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Hong‐Jin, Li, Yan, Wang, De‐Yu, Yuan, Hai‐Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642690/ https://www.ncbi.nlm.nih.gov/pubmed/34766437 http://dx.doi.org/10.1111/jcmm.17051

Ejemplares similares

Pharmacological rationale for antihypertensive drug choice on COVID‐19–affected patients: ACEI/ARB might not increase their susceptibility
por: Zhao, Hong‐Jin, et al.
Publicado: (2020)

Is there a difference in the effect between the ACEI and ARB on COVID‐19?
por: Chen, Jie, et al.
Publicado: (2020)

COVID-19 is more severe in patients with hypertension; ACEI/ARB treatment does not influence clinical severity and outcome
por: Hu, Jianhua, et al.
Publicado: (2020)

In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension
por: Yuan, Yuan, et al.
Publicado: (2020)

Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension
por: Li, Gang, et al.
Publicado: (2020)

Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients
por: Bertsimas, Dimitris, et al.
Publicado: (2021)

Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
por: Huang, Ying, et al.
Publicado: (2020)

The role of ACEIs/ARBs in COVID-19: Friend or foe?
por: Zhou, Zhe, et al.
Publicado: (2020)

Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19
por: Khan, Sikandar Hayat, et al.
Publicado: (2020)

ACEIs and ARBs and Their Correlation with COVID-19: A Review
por: Yehualashet, Awgichew Shewasinad, et al.
Publicado: (2020)

Withdrawal of ACEIs or ARBs in hospitalised patients with COVID-19
Publicado: (2021)

Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension
por: Ma, Jing, et al.
Publicado: (2021)

ACEI/ARB Drug Therapy in COVID-19 Patients: Yes Or No?
por: Gong, Jin, et al.
Publicado: (2021)

ACEI inhibitors and ARBs do not increase severity of COVID-19
Publicado: (2020)

Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB
por: Rico-Mesa, Juan Simon, et al.
Publicado: (2020)

Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI
por: Ma, Cong, et al.
Publicado: (2012)

Mortality in COVID-19 patients treated with ACEIs/ARBs: Re-estimated meta-analysis results following the Mehra et al. retraction
por: Alamer, Ahmad, et al.
Publicado: (2020)

Administration of ACEI or ARB in chronic kidney disease patients with concomitant SARS-CoV-2 respiratory infection()
por: Mateo Gómez, Cristina, et al.
Publicado: (2021)

Effects of ACEI and ARB on COVID-19 patients: A meta-analysis
por: Xue, Yang, et al.
Publicado: (2020)

Safety of ACEi and ARB in COVID‐19 management: A retrospective analysis
por: Kumar, Sabina, et al.
Publicado: (2022)

Temporal variation, socioeconomic status, and out‐of‐hospital deaths as factors that influence mortality rates among hospitalized COVID‐19 patients receiving ACEIs/ARBs
por: Aftab, Owais M., et al.
Publicado: (2022)

COVID-19, ACEI/ARBs, and Gastrointestinal Symptoms: The Jury Is Still Out on the Association
por: Parigi, Tommaso Lorenzo, et al.
Publicado: (2021)

ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror
por: Kelleni, Mina T.
Publicado: (2020)

Comparing clinical outcomes of ARB and ACEi in patients hospitalized for acute COVID-19
por: Hamada, Seiji, et al.
Publicado: (2023)

Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19
por: Huang, Nancy Xurui, et al.
Publicado: (2023)

Effects of ACEIs Versus ARBs on Proteinuria or Albuminuria in Primary Hypertension: A Meta-Analysis of Randomized Trials
por: Xu, Rui, et al.
Publicado: (2015)

ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking
por: Onweni, Chidinma L., et al.
Publicado: (2020)

Antihypertensive Therapy by ACEI/ARB Is Associated With Intestinal Flora Alterations and Metabolomic Profiles in Hypertensive Patients
por: Dong, Ying, et al.
Publicado: (2022)

ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis
por: Zhang, Xue, et al.
Publicado: (2020)

MicroRNA Expression Profile in CAD Patients and the Impact of ACEI/ARB
por: Weber, Martina, et al.
Publicado: (2011)

ARNI versus ACEI/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction
por: She, Jianqing, et al.
Publicado: (2021)

The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy
por: Sun, Liping, et al.
Publicado: (2023)

Comparison of Effects of ACEIs and ARBs on Albuminuria and Hyperkalemia in Indonesian Hypertensive Type 2 Diabetes Mellitus Patients
por: Agustina, Putri S., et al.
Publicado: (2020)

Effects of ACEI/ARB or CCB use on atrial fibrillation in hypertensive patients following permanent pacemaker implantation
por: Liu, Zhijie, et al.
Publicado: (2023)

The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents
por: De Spiegeleer, Anton, et al.
Publicado: (2020)

Severity of COVID-19 infection in ACEI/ARB users in specialty hospitals: A retrospective cohort study
por: Alrashed, Ahmed A., et al.
Publicado: (2021)

Text mining online disinformation about antihypertensive agents ACEI/ARB and COVID-19 on Sina Weibo
por: Wang, Chunli, et al.
Publicado: (2023)

Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients
por: Wang, Wenjun, et al.
Publicado: (2021)

Accepting Medication Therapy Management Recommendations to Add ACEIs or ARBs in Diabetes Care
por: Hurwitz, Jason T., et al.
Publicado: (2016)

Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis
por: Liu, Dong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_43jbdos6ubkf0dmcm62badjpm3